ProfileGDS5678 / 1423518_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 86% 87% 89% 87% 88% 89% 87% 87% 87% 86% 87% 86% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6561987
GSM967853U87-EV human glioblastoma xenograft - Control 26.519986
GSM967854U87-EV human glioblastoma xenograft - Control 36.6519987
GSM967855U87-EV human glioblastoma xenograft - Control 47.1380989
GSM967856U87-EV human glioblastoma xenograft - Control 56.7312287
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.6288688
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.8688889
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.6560587
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6263487
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6506787
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4733586
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.7171387
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5573686
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.6576887